10/31/2026
A HUGE WIN for advocates of medical freedom and patient choice.
RFK Jr. and HHS are moving to temporarily allow physician supervised access to six peptides that federal regulators had previously restricted.
The policy would let licensed compounders provide BPC-157, TB-500, MOTS-c, Semax, Epitalon, and KPV with prescriptions, testing, traceable ingredients, and safety reporting.
Instead of forcing patients toward unregulated gray and black markets, HHS wants to bring access back under legitimate medical supervision.
It is a major shift toward putting more treatment decisions in the hands of patients and their doctors.
